; and (2) in implementing this subsection, solicit input from States, Tribes, localities, and nongovernmental entities, including organizations representing patients, health care providers, researchers, and industry regarding scientific advances, research questions, and surveillance activities. (c) Membership The members of the Working Group shall represent a diversity of scientific disciplines and shall be composed of the following members: (1) Federal members Seven Federal members, consisting of one or more representatives of each of the following: (A) The Office of the Assistant Secretary for Health, who shall serve as Chair. (B) The Food and Drug Administration. (C) The Centers for Disease Control and Prevention. (D) The National Institutes of Health, who shall serve as Vice Chair. (E) Such other agencies and offices of the Department of Health and Human Services as the Secretary determines appropriate. (2) Non-Federal public members Seven non-Federal public members, consisting of representatives of the following categories: (A) Physicians, veterinarians, and other medical providers with experience in diagnosing and treating endemic fungal disease. (B) Scientists or researchers with expertise in endemic fungal disease. (C) Patients who have been diagnosed with an endemic fungal disease and family members or caregivers of such patients, as applicable. (D) Nonprofit organizations that advocate for patients with respect to endemic fungal disease. (E) Other individuals whose expertise is determined by the Secretary to be beneficial to the functioning of the Working Group. (d) Meetings The Working Group shall meet not less frequently than annually. (e) Reporting Not later than 1 year after the date of enactment of this Act, and annually thereafter until termination of the Working Group pursuant to subsection (g), the Secretary shall— (1) submit a report on recommendations received under subsection (b)(1) to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and